San Francisco Reports First Flu Death of the Season
Health officials urge vaccination as flu cases appear early.
San Francisco health officials announced the city's first flu-related death of the 2026-27 flu season. The individual was an adult, but no further details were immediately released by the San Francisco Department of Public Health (SFDPH).
Dr. Susan Philip, San Francisco health officer, emphasized the seriousness of respiratory viruses like influenza and COVID-19, particularly for vulnerable populations. "This sad news reminds us that respiratory viruses such as flu and COVID should be taken very seriously, especially for people who are at higher risk of getting sick," Philip stated. "With fall festivities approaching, we want people to stay healthy and do all the fun and joyful things they want to do. Vaccines help make this happen."
Data from the California Department of Public Health indicates that 26 individuals have died from the flu statewide this season, though it is unclear if the San Francisco fatality is included in this total. These deaths have occurred relatively early in the typical respiratory virus season, as the Centers for Disease Control and Prevention (CDC) usually tracks the official start of flu season as beginning in another two weeks.
Nationally, current levels of respiratory virus activity are reported as "very low" by the CDC. While influenza can circulate year-round, cases commonly rise in the fall and winter months. The CDC recommends individuals receive their flu vaccine before the end of October.
Anyone over the age of 6 months is eligible for a flu vaccine, with older adults (over 65) potentially eligible for a higher-dose version. Flu shots are widely available at pharmacies and doctor's offices, and are frequently covered by health insurance.
The SFDPH also advises staying up-to-date with COVID and RSV vaccinations, aligning with state health department recommendations. The updated 2026-27 COVID vaccine is recommended for specific age groups, including young children, older adults, individuals with risk factors, pregnant individuals, and those in close contact with at-risk populations. The RSV vaccine is recommended for older adults and pregnant individuals, with specific criteria for eligibility.
Additionally, an injectable monoclonal antibody shot is available to protect infants younger than 8 months whose mothers did not receive a vaccine during pregnancy, and for high-risk children aged 8 to 19 months.